NASDAQ:CORT - Corcept Therapeutics Stock Price, Price Target & More

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its earnings results on Tuesday, May, 8th. The biotechnology company reported $0.19 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.18 by $0.01. The biotechnology company had revenue of $57.66 million for the quarter, compared to the consensus estimate of $58.18 million. Corcept Therapeutics had a return on equity of 46.78% and a net margin of 75.05%. The business's quarterly revenue was up 108.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.06 EPS. View Corcept Therapeutics' Earnings History.

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Corcept Therapeutics.

4 brokerages have issued 12 month target prices for Corcept Therapeutics' stock. Their predictions range from $20.00 to $32.00. On average, they anticipate Corcept Therapeutics' stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 115.4% from the stock's current price. View Analyst Ratings for Corcept Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Corcept Therapeutics include Catalent (CTLT), Ionis Pharmaceuticals (IONS), FibroGen (FGEN), Loxo Oncology (LOXO), United Therapeutics (UTHR), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL) and Array Biopharma (ARRY).

News stories about CORT stock have been trending somewhat positive on Friday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Corcept Therapeutics earned a news sentiment score of 0.15 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.46 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Corcept Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include AJ Wealth Strategies LLC (0.38%), Denali Advisors LLC (0.20%), Municipal Employees Retirement System of Michigan (0.02%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright, Renee D Gala and Robert S Fishman. View Institutional Ownership Trends for Corcept Therapeutics.

CORT stock was sold by a variety of institutional investors in the last quarter, including Denali Advisors LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Corcept Therapeutics company stock in the last year include G Leonard Baker Jr and Robert S Fishman. View Insider Buying and Selling for Corcept Therapeutics.

CORT stock was bought by a variety of institutional investors in the last quarter, including AJ Wealth Strategies LLC and Xact Kapitalforvaltning AB. Company insiders that have bought Corcept Therapeutics stock in the last two years include Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CORT stock can currently be purchased for approximately $13.00.

Corcept Therapeutics has a market capitalization of $1.57 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]